While sequencing technology is getting better and faster, it still isn't quite ready to be put to frequent use in the oncology ward, write the Wellcome Trust Center for Human Genetics' Danny Ulahannan and colleagues in a review in the British Journal of Cancer.

In the research setting, they note, there are still challenges in calling low-frequency variants that appear in cancer genomes as well as issues in identifying structural and copy-number variants.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

This Week in Nature

Electric DNA

The Pair of Them

Sequencing to Go

Following the Curve

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.